Streetbeat News

Analyst Ratings

LTRX

Needham analyst Ryan Koontz has reiterated a Buy rating on Lantronix (NASDAQ:LTRX) and maintained a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:48 am

AVGO

Goldman Sachs analyst Toshiya Hari has maintained a Buy rating on Broadcom (NASDAQ:AVGO) and raised the price target from $185 to $190.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:47 am

ALRM

Goldman Sachs has initiated coverage on Alarm.com Holdings with a Neutral rating and set a price target of $64.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:44 am

CNM

Goldman Sachs analyst Joe Ritchie has maintained a Neutral rating on Core & Main (NYSE:CNM) while lowering the price target from $57 to $50.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:41 am

KALV

HC Wainwright & Co. has reiterated its Buy rating for KalVista Pharma, maintaining a price target of $20. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:39 am

BUR

Deutsche Bank has initiated coverage on Burford Capital with a Buy rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:38 am

HUBB

Deutsche Bank has upgraded Hubbell (NYSE:HUBB) from Hold to Buy, increasing the price target from $431 to $441.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:36 am

BTAI

HC Wainwright & Co. has reiterated its Buy rating for BioXcel Therapeutics, maintaining a price target of $7. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:35 am

CNTB

HC Wainwright & Co. has reiterated its Buy rating for Connect Biopharma Holdings (NASDAQ:CNTB) and maintained a price target of $8, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:33 am

PATH

B of A Securities has maintained a Neutral rating on UiPath (NYSE:PATH) while raising its price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:32 am